Cytosorbents Corporation (CTSO)
| Market Cap | 35.78M -47.5% |
| Revenue (ttm) | 37.06M +4.1% |
| Net Income | -8.20M |
| EPS | -0.13 |
| Shares Out | 62.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 92,728 |
| Open | 0.6100 |
| Previous Close | 0.5859 |
| Day's Range | 0.5700 - 0.6100 |
| 52-Week Range | 0.4992 - 1.3900 |
| Beta | 1.44 |
| Analysts | Buy |
| Price Target | 5.38 (+842.87%) |
| Earnings Date | May 13, 2026 |
About CTSO
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammator... [Read more]
Financial Performance
In 2025, Cytosorbents's revenue was $37.06 million, an increase of 4.12% compared to the previous year's $35.60 million. Losses were -$8.20 million, -60.43% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CTSO stock is "Buy." The 12-month stock price target is $5.38, which is an increase of 842.87% from the latest price.
News
CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
PRINCETON, N.J., April 30, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...
Cytosorbents Earnings Call Transcript: Q4 2025
Record 2025 revenue was driven by international growth and new innovations, offset by German restructuring. Gross margin improved, cost reductions were implemented, and the company targets cash flow break even in H2 2026 while advancing DrugSorb-ATR FDA approval.
CytoSorbents reports Q4 adjusted EPS (7c) vs. (3c) last year
Reports Q4 revenue $9.23M vs. $9.15M last year. “2025 was a transitional year for our business as we made good progress in four key objectives,” stated Dr. Phillip Chan, CEO…
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2025 revenue of $37.1 million, up 4% year-over-year, and 71% Full-year gross margins Enhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in Novembe...
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
PRINCETON, N.J., March 5, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using bl...
CytoSorbents sees Q4 revenue $9.2M, consensus $9.85M
Fourth quarter gross margin is expected to be in the range of 73%-75%, compared to 71% in the fourth quarter of 2024, and 70% in the third quarter of 2025.
CytoSorbents sees FY25 revenue $37M, consensus $37.67M
Full-year gross margin is expected to be approximately 72%, compared to 71% for full-year 2024.
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update
Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75% DrugSorb®-ATR De Novo...
Cytosorbents Transcript: Fireside Chat
The discussion highlighted the company's regulatory and financial strategies, focusing on DrugSorb-ATR's U.S. approval pathway and the strong clinical need for blood purification in cardiac surgery. Subgroup analyses and European data support efficacy, with FDA approval targeted for mid-2026.
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
PRINCETON, N.J. , Dec. 10, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...
Cytosorbents Transcript: Jefferies London Healthcare Conference 2025
A platform blood purification technology is driving growth in critical care and cardiac surgery, with strong international sales and a focus on U.S. regulatory approval for a breakthrough device targeting bleeding in patients on blood thinners. Plans include a direct sales launch, expansion to new indications, and achieving cash flow breakeven in Q1 2026.
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
PRINCETON, N.J. , Nov. 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using ...
CytoSorbents price target lowered to 75c from $1 at H.C. Wainwright
H.C. Wainwright analyst Sean Lee lowered the firm’s price target on CytoSorbents (CTSO) to 75c from $1 and keeps a Neutral rating on the shares. The firm reduced estimates to…
Cytosorbents Earnings Call Transcript: Q3 2025
Q3 2025 revenue rose 10% year-over-year to $9.5 million, with gross margin improving to 70%. Strategic cost reductions and a restructured loan agreement support the goal of cash flow break-even by Q1 2026, while a new FDA submission for DrugSorb ATR is planned for early 2026.
CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c)
Reports Q3 revenue $9.5M, consensus $10.02M. “We are pleased with our third quarter results led by record sales in our distributor territories, strong sales in our other direct markets, and…
CytoSorbents implemented workforce and cost reduction program
CytoSorbents (CTSO) announced the implementation of a strategic Workforce and cost reduction plan to further reduce costs, optimize operations, and accelerate the path to cash-flow profitability. This...
CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update
Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with an additional $2.5 million of cash, and ex...
CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
PRINCETON, N.J. , Nov. 11, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
PRINCETON, N.J. , Oct. 30, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...
In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer
PRINCETON, N.J. , Oct. 28, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...
CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen
PRINCETON, N.J. , Sept. 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using ...
CytoSorbents provides DrugSorb-ATR regulatory update
CytoSorbents (CTSO) provided a regulatory update on DrugSorb-ATR. CytoSorbents CytoSorbents’ flagship product, CytoSorb, is approved in the EU and distributed in over 70 countries worldwide. CytoSorbe...
CytoSorbents Provides DrugSorb-ATR Regulatory Update
PRINCETON, N.J. , Sept. 16, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using...
Cytosorbents Transcript: H.C. Wainwright 27th Annual Global Investment Conference
CytoSorb and DrugSorb-ATR blood purification technologies are driving growth, with strong clinical evidence supporting reduced mortality and complications in critical care and cardiac surgery. Regulatory progress continues for DrugSorb-ATR in North America, while financial performance remains robust with high margins and expanding sales.